Cargando…
CU06-1004 as a promising strategy to improve anti-cancer drug efficacy by preventing vascular leaky syndrome
Background: Interleukin-2 (IL-2) is the first cancer therapeutic agent with an immunomodulatory function. Although it has been experimentally proven to be effective against metastatic renal cell carcinoma and metastatic melanoma, the clinical application of high-dose IL-2 (HDIL-2) has been limited b...
Autores principales: | Park, Songyi, Lee, Sunghye, Kim, Dongyeop, Kim, Hyejeong, Kwon, Young-Guen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499177/ https://www.ncbi.nlm.nih.gov/pubmed/37711172 http://dx.doi.org/10.3389/fphar.2023.1242970 |
Ejemplares similares
-
CU06-1004 Alleviates Experimental Colitis by Modulating Colonic Vessel Dysfunction
por: Kim, Ye-Seul, et al.
Publicado: (2020) -
Efficacy of CU06-1004 via regulation of inflammation and endothelial permeability in LPS-induced acute lung injury
por: Kim, Yeomyeong, et al.
Publicado: (2023) -
Long-term administration of CU06-1004 ameliorates cerebrovascular aging and BBB injury in aging mouse model
por: Kim, Hyejeong, et al.
Publicado: (2023) -
CU06-1004-Induced Vascular Normalization Improves Immunotherapy by Modulating Tumor Microenvironment via Cytotoxic T Cells
por: Park, Songyi, et al.
Publicado: (2021) -
CU06-1004 (endothelial dysfunction blocker) ameliorates astrocyte end-feet swelling by stabilizing endothelial cell junctions in cerebral ischemia/reperfusion injury
por: Kim, Dong Young, et al.
Publicado: (2020)